Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cyanotech Corporation (CYAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CYAN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -26.81% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.53M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) - | Beta -0.24 | 52 Weeks Range 0.23 - 0.89 | Updated Date 06/29/2025 |
52 Weeks Range 0.23 - 0.89 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date 2025-06-20 | When - | Estimate - | Actual -0.09 |
Profitability
Profit Margin -13.23% | Operating Margin (TTM) -7.18% |
Management Effectiveness
Return on Assets (TTM) -6.16% | Return on Equity (TTM) -30.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14199886 | Price to Sales(TTM) 0.1 |
Enterprise Value 14199886 | Price to Sales(TTM) 0.1 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA 21.94 | Shares Outstanding 7232220 | Shares Floating 4836617 |
Shares Outstanding 7232220 | Shares Floating 4836617 | ||
Percent Insiders 38.34 | Percent Institutions - |
Upturn AI SWOT
Cyanotech Corporation
Company Overview
History and Background
Cyanotech Corporation, founded in 1983, is a world leader in microalgae technology, producing high-value nutritional and health products from microalgae.
Core Business Areas
- Human Nutrition: Production and sale of nutritional supplements derived from microalgae, including spirulina and astaxanthin, for human consumption.
- Animal Nutrition: Production and sale of microalgae-based products for animal feed and nutrition, particularly for aquaculture and livestock.
Leadership and Structure
Cyanotech is led by a management team with expertise in biotechnology, manufacturing, and marketing. The organizational structure includes departments for research and development, production, sales, and administration.
Top Products and Market Share
Key Offerings
- BioAstin Hawaiian Astaxanthin: A potent antioxidant derived from microalgae, marketed as a dietary supplement for joint, eye, skin, and overall health. Competitors include Valensa International and AlgaeHealth. Market share data is not publicly disclosed. Revenue is not broken down by individual product publicly but it is a substantial portion of overall revenue.
- Hawaiian Spirulina Pacifica: A nutrient-rich blue-green algae supplement, sold as a source of protein, vitamins, and antioxidants. Competitors include NOW Foods and Nutrex Hawaii. Market share data is not publicly disclosed. Revenue is not broken down by individual product publicly but it is a substantial portion of overall revenue.
Market Dynamics
Industry Overview
The nutraceuticals market is growing, driven by increasing consumer awareness of health and wellness. The demand for natural and sustainable ingredients is a key trend.
Positioning
Cyanotech is positioned as a premium supplier of high-quality microalgae-based products, leveraging its proprietary cultivation technology and Hawaiian location for marketing advantage.
Total Addressable Market (TAM)
The global nutraceuticals market is estimated at hundreds of billions of dollars. Cyanotech is positioned within a niche segment of this market, focusing on microalgae-derived products. The astaxanthin market is around 1 billion USD and is expected to grow. The spirulina market is estimated at over $500 million USD and is growing. Cyanotech is a significant, but not dominant, player in these areas.
Upturn SWOT Analysis
Strengths
- Proprietary cultivation technology
- High-quality products
- Brand reputation
- Hawaiian location provides marketing appeal
Weaknesses
- Relatively small size compared to competitors
- Concentration on microalgae-based products
- Vulnerability to climate-related disruptions
- Limited financial resources compared to larger players
Opportunities
- Expanding into new markets and applications
- Developing new microalgae-based products
- Partnering with larger companies
- Increasing consumer awareness of health benefits
Threats
- Competition from larger nutraceutical companies
- Price pressure from lower-cost producers
- Regulatory changes
- Fluctuations in raw material prices
Competitors and Market Share
Key Competitors
- NUTX
- DSM
- ALGJF
Competitive Landscape
Cyanotech competes with larger nutraceutical companies, focusing on niche segments and high-quality products. It needs to differentiate through innovation and marketing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, driven by increasing demand for natural supplements.
Future Projections: Future projections depend on market trends, competition, and the company's ability to innovate and expand.
Recent Initiatives: Recent initiatives could include new product launches, partnerships, or marketing campaigns.
Summary
Cyanotech is a niche player in the nutraceuticals market, focused on high-quality microalgae-based products. Its strengths lie in its brand reputation and proprietary technology, but it faces challenges from larger competitors and price pressure. Future success depends on expanding its product line, securing partnerships, and effectively marketing its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, industry reports, news articles, SEC filings (when available).
- Google Finance
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated. Financial performance details are limited due to lack of direct access to financial statements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyanotech Corporation
Exchange NASDAQ | Headquaters Kailua-Kona, HI, United States | ||
IPO Launch date 1993-06-22 | President, CEO & Director Mr. Matthew Keith Custer | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 83 | Website https://www.cyanotech.com |
Full time employees 83 | Website https://www.cyanotech.com | ||
Cyanotech Corporation, an agricultural company, engages in the production of natural products derived from microalgae worldwide. The company offers BioAstin Hawaiian Astaxanthin, a natural antioxidant to enhance skin, and to support eye, joint, brain, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement to support natural energy, immune system, and cardiovascular health, as well as a source of protein, antioxidant carotenoids, and essential nutrients. It also provides contract extraction and research and development services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health food, cosmetic manufacturers and nutraceuticals, and dietary supplement markets. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.